Skip to content

US · VIVS · BIOTECHNOLOGY

VivoSim Labs, Inc. (VIVS) intrinsic value and stock valuation

$0.26as of 2026-11-21 · Mkt cap 933.7K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

VivoSim Labs, Inc. DCF and intrinsic value

InvestorsCraft values VIVS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VIVS’s statements →

VivoSim Labs, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 vivosim.ai

How the business is doing

Fiscal 2011–2026, USD

Revenue
$130K
20112026
Net income
-$-13.84M
20112026
Free cash flow
-$-10.83M
20112026
Total equity
-$-1.1M
20112026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2026, USD
20262025202420232022
Revenue$130K$140K$110K$370K$1.5M
Operating income-$-11.22M-$-12.62M-$-15.09M-$-17.73M-$-11.48M
Net income-$-13.84M-$-2.49M-$-14.67M-$-17.26M-$-11.45M
EPSd-$-5.34M-$-1.71M-$-19.3M-$-23.64M-$-15.68M
Operating cash flow-$-10.83M-$-9.46M-$-14.65M-$-12.41M-$-8.45M
Capital expenditure$0.00-$-10K-$-40K-$-400K-$-410K
Free cash flow-$-10.83M-$-9.47M-$-14.7M-$-12.8M-$-8.86M
Total assets$7.39M$14.7M$6.35M$20.3M$33.3M
Total debt$450K$940K$1.39M$1.8M$2.18M
Net debt-$-4.58M-$-10.37M-$-1.51M-$-13.5M-$-26.49M
Total equity-$-1.1M$10.5M$3.6M$15.3M$30.2M
Cash and short-term investments$5.02M$11.3M$2.9M$16M$28.7M
Income statement
20262025202420232022
Revenue$130K$140K$110K$370K$1.5M
Cost of revenue$0.00$10K$0.00$0.00$0.00
Gross profit$130K$140K$110K$370K$1.5M
Research and development expenses$4.19M$5.03M$5.5M$8.88M$3.32M
Selling, general and administrative expenses$7.17M$7.69M$9.64M$9.09M$9.63M
Other expenses$0.00$40K$50K$130K$30K
Operating expenses$11.4M$12.8M$15.2M$18.1M$13M
Cost and expenses$11.4M$12.8M$15.2M$18.1M$13M
Interest income$270K$140K$410K$450K$10K
Interest expense$10K$10K$0.00$0.00$0.00
Depreciation and amortization$0.00$270K$280K$290K$140K
Ebitda-$-13.57M-$-2.21M-$-14.39M-$-16.96M-$-11.3M
Operating income-$-11.22M-$-12.62M-$-15.09M-$-17.73M-$-11.48M
Total other income/expenses, net-$-2.35M$10.1M$420K$470K$30K
Income before tax-$-13.58M-$-2.49M-$-14.67M-$-17.26M-$-11.45M
Income tax expense-$0.00$0.00$0.00$0.00$0.00
Net income-$-13.84M-$-2.49M-$-14.67M-$-17.26M-$-11.45M
Weighted average shares outstanding$2.59M$1.46M$760K$730K$730K
Weighted average diluted shares outstanding$2.59M$1.46M$760K$730K$730K
Balance sheet
20262025202420232022
Cash and short-term investments$5.02M$11.3M$2.9M$16M$28.7M
Net receivables$1.05M$30K$30K$150K$0.00
Inventory$0.00$0.00$300K$0.00$0.00
Total current assets$6.63M$12.1M$3.94M$17.1M$29.5M
Property, plant and equipment, net$610K$1.29M$1.97M$2.61M$2.81M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$760K$2.52M$2.41M$3.27M$3.76M
Total assets$7.39M$14.7M$6.35M$20.3M$33.3M
Accounts payable$1.02M$1.64M$630K$330K$410K
Short-term debt$450K$520K$510K$490K$480K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.79M$3.74M$1.86M$3.67M$1.38M
Long-term debt$0.00$420K$890K$1.31M$1.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.7M$420K$890K$1.31M$1.7M
Capital lease obligations$450K$940K$1.39M$1.8M$2.18M
Total liabilities$8.48M$4.16M$2.75M$4.98M$3.09M
Common stock$0.00$0.00$10K$10K$10K
Retained earnings-$-356M-$-342.16M-$-339.67M-$-325M-$-307.74M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-1.1M$10.5M$3.6M$15.3M$30.2M
Total investments$0.00$0.00$0.00$710K$0.00
Total debt$450K$940K$1.39M$1.8M$2.18M
Net debt-$-4.58M-$-10.37M-$-1.51M-$-13.5M-$-26.49M
Cash flow statement
20262025202420232022
Net income-$-13.84M-$-2.49M-$-14.67M-$-17.26M-$-11.45M
Depreciation and amortization$210K$270K$280K$290K$140K
Stock-based compensation$300K$530K$1.51M$2.38M$2.26M
Change in working capital-$-680K$1.04M-$-2.02M$2.31M$600K
Accounts receivable-$0.00$0.00$120K-$-150K$0.00
Inventory$0.00-$-500K-$-300K$0.00$0.00
Accounts payable-$-620K$1.02M$300K-$-150K$130K
Net cash provided by operating activities-$-10.83M-$-9.46M-$-14.65M-$-12.41M-$-8.45M
Investments in property, plant and equipment$0.00-$-10K-$-40K-$-400K-$-410K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$90K$9.03M$820K-$-970K-$-410K
Common stock issued$4.81M$8.85M$1.44M$0.00$250K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.45M$8.85M$1.44M$0.00$200K
Net change in cash-$-6.29M$8.41M-$-12.4M-$-13.37M-$-8.66M
Cash at end of period$5.17M$11.5M$3.04M$15.4M$28.8M
Operating cash flow-$-10.83M-$-9.46M-$-14.65M-$-12.41M-$-8.45M
Capital expenditure$0.00-$-10K-$-40K-$-400K-$-410K
Free cash flow-$-10.83M-$-9.47M-$-14.7M-$-12.8M-$-8.86M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About VivoSim Labs, Inc.

        VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

        CEO
        Keith Murphy
        Employees
        15
        Beta
        1.40

        Explore

        Frequently asked questions

        What is the intrinsic value of VivoSim Labs, Inc. (VIVS)?

        InvestorsCraft does not currently publish an intrinsic value for VIVS. How the IC value is calculated.

        Is VIVS undervalued?

        InvestorsCraft does not publish an undervaluation signal for VIVS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.